Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparative evaluation of ipss-m and cpss-mol in CMML: Impact of molecular markers on prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

YOYotaro OchiLSLaurenz SteinerVRVladimir Riabov

Discussion

Loading...

Member takes

Overview

Retrospective analysis improved prognosis in CMML using genetic alterations and IPSS-M, suggesting enhanced stratification.

Key Points

  • To compare the prognostic performance of IPSS-M and CPSS-Mol in patients with chronic myelomonocytic leukemia (CMML).
  • Retrospective analysis of 480 CMML patients across international and Japanese cohorts.
  • Calculated CPSS-Mol and IPSS-M scores based on clinical and genetic parameters.
  • Used Kaplan-Meier estimates for overall survival analysis and log-rank method to test risk group differences.
  • Performed univariate and multivariate Cox regression to identify independent prognostic factors.
  • IPSS-M showed superior performance in risk stratification compared to CPSS-Mol (c-index: 0.760 vs. 0.695).
  • Among 480 patients, IPSS-M classified risk with better sensitivity across MD-CMML and MP-CMML subtypes.
  • High-risk OS medians were 9.6 months for IPSS-M and 13.6 months for CPSS-Mol; low-risk OS medians were 110.7 months vs. 66.0 months, respectively.
  • Key independent prognostic factors included hemoglobin levels, age, and low cytogenetic risk profile.

Cite This Study

Ochi et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d842https://doi.org/10.1182/blood-2025-3860
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification2024 · 7 citations
  2. 2Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)2025
  3. 3Prognostic stratification in MDS/MPN syndromes other than CMML: an Italian multicenter real-world study2026
  4. 4Validation of the Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic neoplasms (MDS) and comparison with the revised International Prognostic Scoring System (IPSS-R) in Chinese Population: A Multicenter Retrospective Study.2024 · 1 citations
  5. 5Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms2025